Final Salvo? Galvus Infringement Case Simmers In India
Natco has sprung a challenge to Novartis’ vildagliptin patent in India, months before its expiry. The Indian firm will hold back further release of its product on the market amid legal action and it remains to be seen if Novartis will pursue damages.
You may also be interested in...
Legal proceedings around Novartis' Galvus patent in India appear to have taken an interesting turn, with generic challenger Wockhardt indicating that it will retract its application for the revocation of the patent on the diabetes drug.
The Indian patent office has declined to "proceed further" with Novartis' application for vildagliptin and metformin in a single formulation (Galvumet) citing lack of inventive step and objections around the "sufficiency of disclosure".
Pre-emptive intellectual property rights-related legal action appears to be on the uptick in India with Novartis now moving the Delhi High Court against four more Indian firms alleging infringement of its patent concerning the DPP-4 inhibitor for diabetes, vildagliptin.